![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The outcome of 24 vs. 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study
|
|
|
Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
Hugo Cheinquer,*Mitchell L. Shiffman, Stefan Zeuzem, Christoph Berg, Thomas Berg, Cláudio de Figueiredo- Mendes, Gregory Dore, Maria Lucia Ferraz, Maria Cassia Mendes-Correa, Maria Patelli-Lima, Edison Parise, Alma Perez-Rios, Tania Reuter, Arun Sanyal, Stephen Shafran, Marc Hohmann, Fernando Tatsch
*Hospital de Clínicas de Porto Alegre, Brazil
![AASLD1.gif](../images/112612/112612-2/AASLD1.gif)
![AASLD2.gif](../images/112612/112612-2/AASLD2.gif)
![AASLD3.gif](../images/112612/112612-2/AASLD3.gif)
![AASLD4.gif](../images/112612/112612-2/AASLD4.gif)
![AASLD5.gif](../images/112612/112612-2/AASLD5.gif)
![AASLD6.gif](../images/112612/112612-2/AASLD6.gif)
![AASLD7.gif](../images/112612/112612-2/AASLD7.gif)
![AASLD8.gif](../images/112612/112612-2/AASLD8.gif)
![AASLD9.gif](../images/112612/112612-2/AASLD9.gif)
![AASLD10.gif](../images/112612/112612-2/AASLD10.gif)
![AASLD11.gif](../images/112612/112612-2/AASLD11.gif)
![AASLD12.gif](../images/112612/112612-2/AASLD12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|